BACKGROUND: Despite recent advances in earlier detection and improvements in chemotherapy, the 5-year survival rate of patients with metastatic colorectal carcinoma remains poor. Immunotherapy is a potentially effective therapeutic approach to the treatment of colorectal carcinoma. Preclinical studies have supported the antitumor activity of immunization with a granulocyte-macrophage colony-stimulating factor (GM-CSF) producing murine colon tumor cell vaccine. METHODS: A novel colorectal cancer vaccine composed of irradiated, allogeneic human colon cancer cells and GM-CSF-producing bystander cells was developed and tested in combination with a single intravenous low dose of cyclophosphamide in a phase 1 study of patients with metastatic colorectal cancer. RESULTS: A total of nine patients were enrolled onto and treated in this study. Six patients had a history of colorectal adenocarcinoma hepatic metastases and underwent curative metastasectomy, while three other patients had unresectable stage IV disease. This study demonstrates the safety and feasibility of this vaccine administered in patients with metastatic colorectal cancer. At last follow-up, the six patients who underwent curative metastasectomy survived longer than 36 months, and four of these six patients were without disease recurrence. Immunologic correlate results suggest that the GM-CSF-producing colon cancer vaccine enhances the production of anti-MUC1 antibodies. CONCLUSIONS: This vaccine is feasible and safe. Future investigation of the efficacy and antitumor immunity of this vaccine is warranted.
BACKGROUND: Despite recent advances in earlier detection and improvements in chemotherapy, the 5-year survival rate of patients with metastatic colorectal carcinoma remains poor. Immunotherapy is a potentially effective therapeutic approach to the treatment of colorectal carcinoma. Preclinical studies have supported the antitumor activity of immunization with a granulocyte-macrophage colony-stimulating factor (GM-CSF) producing murinecolon tumor cell vaccine. METHODS: A novel colorectal cancer vaccine composed of irradiated, allogeneic humancolon cancer cells and GM-CSF-producing bystander cells was developed and tested in combination with a single intravenous low dose of cyclophosphamide in a phase 1 study of patients with metastatic colorectal cancer. RESULTS: A total of nine patients were enrolled onto and treated in this study. Six patients had a history of colorectal adenocarcinoma hepatic metastases and underwent curative metastasectomy, while three other patients had unresectable stage IV disease. This study demonstrates the safety and feasibility of this vaccine administered in patients with metastatic colorectal cancer. At last follow-up, the six patients who underwent curative metastasectomy survived longer than 36 months, and four of these six patients were without disease recurrence. Immunologic correlate results suggest that the GM-CSF-producing colon cancer vaccine enhances the production of anti-MUC1 antibodies. CONCLUSIONS: This vaccine is feasible and safe. Future investigation of the efficacy and antitumor immunity of this vaccine is warranted.
Authors: Ahmedin Jemal; Melissa M Center; Carol DeSantis; Elizabeth M Ward Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-07-20 Impact factor: 4.254
Authors: P Mukherjee; L B Pathangey; J B Bradley; T L Tinder; G D Basu; E T Akporiaye; S J Gendler Journal: Vaccine Date: 2006-11-16 Impact factor: 3.641
Authors: C A Uyl-de Groot; J B Vermorken; M G Hanna; P Verboom; M T Groot; G J Bonsel; C J L M Meijer; H M Pinedo Journal: Vaccine Date: 2005-03-18 Impact factor: 3.641
Authors: Dan Laheru; Eric Lutz; James Burke; Barbara Biedrzycki; Sara Solt; Beth Onners; Irena Tartakovsky; John Nemunaitis; Dung Le; Elizabeth Sugar; Kristen Hege; Elizabeth Jaffee Journal: Clin Cancer Res Date: 2008-03-01 Impact factor: 12.531
Authors: Leisha A Emens; Justin M Asquith; James M Leatherman; Barry J Kobrin; Silvia Petrik; Marina Laiko; Joy Levi; Maithili M Daphtary; Barbara Biedrzycki; Antonio C Wolff; Vered Stearns; Mary L Disis; Xiaobu Ye; Steven Piantadosi; John H Fetting; Nancy E Davidson; Elizabeth M Jaffee Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544
Authors: C Alston James; Peter Ronning; Darren Cullinan; Kelsy C Cotto; Erica K Barnell; Katie M Campbell; Zachary L Skidmore; Dominic E Sanford; S Peter Goedegebuure; William E Gillanders; Obi L Griffith; William G Hawkins; Malachi Griffith Journal: Cancer Res Commun Date: 2021-11
Authors: Tara M Robinson; Gabrielle T Prince; Chris Thoburn; Erica Warlick; Anna Ferguson; Yvette L Kasamon; Ivan M Borrello; Allan Hess; B Douglas Smith Journal: Leuk Lymphoma Date: 2018-04-04
Authors: Samuel C Wagner; Thomas E Ichim; Vladimir Bogin; Wei-Ping Min; Francisco Silva; Amit N Patel; Santosh Kesari Journal: Oncotarget Date: 2017-04-25
Authors: Daniel R Owen; Hui-Li Wong; Melika Bonakdar; Martin Jones; Christopher S Hughes; Gregg B Morin; Steven J M Jones; Daniel J Renouf; Howard Lim; Janessa Laskin; Marco Marra; Stephen Yip; David F Schaeffer Journal: Cold Spring Harb Mol Case Stud Date: 2018-04-02
Authors: Mark Yarchoan; Chiung-Yu Huang; Qingfeng Zhu; Anna K Ferguson; Jennifer N Durham; Robert A Anders; Elizabeth D Thompson; Noah S Rozich; Dwayne L Thomas; Julie M Nauroth; Christina Rodriguez; Arsen Osipov; Ana De Jesus-Acosta; Dung T Le; Adrian G Murphy; Daniel Laheru; Ross C Donehower; Elizabeth M Jaffee; Lei Zheng; Nilofer S Azad Journal: Cancer Med Date: 2019-12-26 Impact factor: 4.452
Authors: Victoria M Kim; Xingyi Pan; Kevin C Soares; Nilofer S Azad; Nita Ahuja; Christopher J Gamper; Alex B Blair; Stephen Muth; Ding Ding; Brian H Ladle; Lei Zheng Journal: JCI Insight Date: 2020-05-07